News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
610,855 Results
Type
Article (53346)
Company Profile (95)
Press Release (557408)
Multimedia
Podcasts (183)
Webinars (26)
Section
Business (181600)
Career Advice (2491)
Deals (29593)
Drug Delivery (172)
Drug Development (72669)
Employer Resources (163)
FDA (16432)
Job Trends (12768)
News (283797)
Policy (30988)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (6)
Academia (2735)
Academic (1)
Accelerated approval (60)
ADA (45)
Adcomms (43)
Allergies (193)
Alliances (40441)
ALS (233)
Alzheimer's disease (2061)
Antibody-drug conjugate (ADC) (542)
Approvals (16797)
Artificial intelligence (767)
ASCO (313)
Autoimmune disease (371)
Automation (60)
Bankruptcy (322)
Best Places to Work (9744)
BIO (70)
Biologics (1)
BIOSECURE Act (23)
Biosimilars (250)
BioSpace Insights (145)
Biotechnology (63)
Bladder cancer (215)
Brain cancer (78)
Breast cancer (805)
Cancer (6430)
Cardiovascular disease (548)
Career advice (2127)
Career pathing (52)
CAR-T (364)
CDC (77)
Celiac Disease (2)
Cell therapy (997)
Cervical cancer (55)
Clinical research (64066)
Collaboration (2160)
Commercialization (6)
Company closure (7)
Compensation (1584)
Complete response letters (118)
COVID-19 (2843)
CRISPR (122)
C-suite (1264)
Cystic fibrosis (158)
Data (8614)
Decentralized trials (3)
Denatured (44)
Depression (201)
Dermatology (108)
Diabetes (666)
Diagnostics (6353)
Digital health (58)
Diversity (9)
Diversity, equity & inclusion (43)
Drug discovery (360)
Drug pricing (242)
Drug shortages (36)
Duchenne muscular dystrophy (336)
Earnings (66751)
Editorial (81)
Employer branding (20)
Employer resources (149)
Events (91622)
Executive appointments (1111)
FDA (20651)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (24)
Frontotemporal dementia (36)
Funding (1816)
Gene editing (260)
Generative AI (66)
Gene therapy (815)
GLP-1 (1225)
Government (4473)
Grass and pollen (8)
Guidances (420)
Healthcare (16434)
Hematology (184)
HIV (101)
Huntington's disease (73)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (124)
Immunology and inflammation (363)
Immuno-oncology (112)
Indications (218)
Infectious disease (3217)
Inflammatory bowel disease (227)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (320)
Interviews (464)
IPO (14618)
IRA (58)
Job creations (3287)
Job search strategy (1724)
JPM (69)
Kidney cancer (26)
Labor market (114)
Layoffs (660)
Leadership (55)
Legal (7284)
Licensing (5)
Liver cancer (106)
Longevity (31)
Lung cancer (845)
Lymphoma (489)
Machine learning (62)
Management (57)
Manufacturing (1140)
Marketing (12)
MASH (226)
Medical affairs (1)
Medical device (12325)
Medtech (12513)
Mergers & acquisitions (16264)
Metabolic disorders (1777)
mRNA (262)
Multiple sclerosis (191)
NASH (23)
Neurodegenerative disease (533)
Neuropsychiatric disorders (132)
Neuroscience (3807)
Neurotech (2)
NextGen: Class of 2026 (5392)
Non-profit (3811)
Now hiring (43)
Obesity (861)
Opinion (338)
Ovarian cancer (248)
Pain (273)
Pancreatic cancer (363)
Parkinson's disease (413)
Partnered (30)
Patents (659)
Patient recruitment (813)
Peanut (67)
People (49790)
Pharmaceutical (28)
Pharmacy benefit managers (36)
Phase 1 (19469)
Phase 2 (27852)
Phase 3 (22203)
Pipeline (10216)
Policy (399)
Postmarket research (2350)
Preclinical (8082)
Press Release (39)
Prostate cancer (354)
Psychedelics (78)
Radiopharmaceuticals (338)
Rare diseases (1321)
Real estate (4771)
Recruiting (68)
Regulatory (25516)
Reports (48)
Research institute (2596)
Resumes & cover letters (414)
Rett syndrome (48)
RNA editing (26)
RSV (88)
Schizophrenia (197)
Series A (306)
Series B (227)
Service/supplier (7)
Sickle cell disease (128)
Special edition (30)
Spinal muscular atrophy (161)
Sponsored (52)
Startups (3134)
State (1)
Stomach cancer (21)
Supply chain (140)
Tariffs (105)
The Weekly (137)
Vaccines (1277)
Venture capital (141)
Weight loss (592)
Women's health (126)
Worklife (25)
Date
Today (112)
Last 7 days (603)
Last 30 days (2087)
Last 365 days (29651)
2026 (17814)
2025 (29243)
2024 (32646)
2023 (36523)
2022 (46867)
2021 (50588)
2020 (47835)
2019 (39030)
2018 (29540)
2017 (29501)
2016 (27946)
2015 (30645)
2014 (24229)
2013 (20078)
2012 (21414)
2011 (21796)
2010 (19788)
Location
Africa (760)
Alabama (86)
Alaska (6)
Arizona (323)
Arkansas (13)
Asia (36057)
Australia (6501)
California (13710)
Canada (3312)
China (1349)
Colorado (540)
Connecticut (612)
Delaware (433)
Europe (88157)
Florida (2133)
Georgia (422)
Hawaii (5)
Idaho (46)
Illinois (1077)
India (98)
Indiana (611)
Iowa (25)
Japan (613)
Kansas (122)
Kentucky (45)
Louisiana (43)
Maine (83)
Maryland (1653)
Massachusetts (9883)
Michigan (315)
Minnesota (726)
Mississippi (5)
Missouri (150)
Montana (18)
Nebraska (25)
Nevada (141)
New Hampshire (71)
New Jersey (3636)
New Mexico (22)
New York (3605)
North Carolina (1732)
North Dakota (9)
Northern California (7051)
Ohio (405)
Oklahoma (22)
Oregon (37)
Pennsylvania (2594)
Puerto Rico (26)
Rhode Island (38)
South America (1128)
South Carolina (88)
South Dakota (2)
Southern California (5421)
Tennessee (211)
Texas (2195)
United States (48061)
Utah (363)
Vermont (2)
Virginia (340)
Washington D.C. (78)
Washington State (1073)
West Virginia (4)
Wisconsin (147)
Wyoming (1)
610,855 Results for "banner alzheimer s institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.
July 30, 2026
·
5 min read
·
Annalee Armstrong
Alzheimer’s disease
Merck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woes
The mid-stage disappointment in Alzheimer’s disease delivers another blow to Neuphoria Therapeutics, which in November last year was forced to launch a strategic business review after a Phase 3 trial in social anxiety disorder failed.
July 2, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
July 10, 2026
·
6 min read
·
Michael Gibney
Alzheimer’s disease
Lilly bets up to $1B+ with AlzeCure in search for next Alzheimer’s act
The star of the licensing agreement, a small-molecule gamma-secretase modulator, will help buff Eli Lilly’s position in Alzheimer’s disease, currently headlined by its anti-amyloid antibody Kisunla.
June 10, 2026
·
2 min read
·
Tristan Manalac
Approvals
Axsome wins first non-antipsychotic FDA approval for Alzheimer’s agitation
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.
May 1, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy
The FDA’s extension will give reviewers more time to review a major amendment to Biogen and Eisai’s application for a subcutaneous induction formulation of Alzheimer’s therapy Leqembi. The new target action date is on Aug. 24.
May 8, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month course of Lilly’s product.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Feinstein Institutes secures $4.9M in NIH grants to advance research in acute inflammation and Alzheimer’s disease
June 30, 2026
·
3 min read
Alzheimer’s disease
AAIC 2026: Biogen delivers hope, validation with anti-tau Alzheimer’s win
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
July 14, 2026
·
5 min read
·
Heather McKenzie
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
1 of 61,086
Next
